| The Importance of Controlling Terminal Complement Activity and Intravascular Hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management" |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| HLA-haploidentical stem cell transplantation in children with inherited bone marrow failure syndromes: A retrospective analysis on behalf of EBMT severe aplastic Anemia and pediatric diseases working parties |
|
American Journal of Hematology |
Aplastic Anemia |
| Paroxysmal nocturnal hemoglobinuria: Where we stand |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Patients with paroxysmal nocturnal hemoglobinuria demonstrate a prothrombotic clotting phenotype which is improved by complement inhibition with eculizumab |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Paroxysmal nocturnal hemoglobinuria: Where are we going |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the COMMANDS Study |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Luspatercept use for lower risk myelodysplastic syndromes: Active but not enough |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
